TGF-β/SMAD signalling is an important inducer of EMT in various cancers.34–36 We found that EEF1A2 overexpression or silencing caused a change in the expression of two key receptors in the TGF-β signalling pathway, TGF-β receptor type I (TβR I) and type II (TβR II). Here, TGFB1 is linked to cancer.